Tue, Sep 16, 2014, 9:08 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

ImmunoCellular Therapeutics, Ltd. Message Board

horse.ghost25 84 posts  |  Last Activity: Jul 24, 2014 3:13 PM Member since: Sep 14, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    catalysts coming

    by horse.ghost25 Jul 24, 2014 9:17 AM
    horse.ghost25 horse.ghost25 Jul 24, 2014 3:13 PM Flag

    it doesn´t make any sense to use the two drugs (Doxo plus Ifo) if you have the same result with one drug (Aldo) with significant less sideeffects.

    Sentiment: Strong Buy

  • Reply to

    PBYI Vs CYTR

    by bnarayan_97 Jul 24, 2014 9:55 AM
    horse.ghost25 horse.ghost25 Jul 24, 2014 10:04 AM Flag

    yep, CYTR trial results have been stellar good.

    Sentiment: Strong Buy

  • horse.ghost25 by horse.ghost25 Jul 24, 2014 9:17 AM Flag

    remember the catalyst coming : they will push the pps to double digits.
    until now the trial data was stellar good and probably will remain to be .
    -- Initiate a global Phase 2b clinical trial of aldoxorubicin as a second-line treatment for small cell lung cancer (SCLC) in the second half of 2014
    -- Announce OS results from the ongoing global Phase 2b clinical trial of aldoxorubicin as a first-line treatment for STS in the second half of 2014
    -- Expand the oncology pipeline by combining the Company’s novel linker platform technology with additional chemotherapeutic agents
    -- Announce preliminary results from the ongoing Phase 2 clinical trial of aldoxorubicin in Glioblastoma Multiforme in the coming year.

    Sentiment: Strong Buy

  • almost a third of the volume sold short on July 22 and 23. Some BOYZ are trying hard to hold pps down. More and more investors will realize the value of CYTX technology. There will be more good news coming in the next months. Good time to accumulate .

  • horse.ghost25 horse.ghost25 Jul 23, 2014 3:32 PM Flag

    more and more investors will realize the technology of CYTX.

    Roth Capital analyst Joseph Pantginis reiterated a Buy rating on CYTX with a $10 price target.

    Pantginis noted, “We see the selection of Cytori’s ADRC’s for the CCTRN’s trial as validating for the company. The CCTRN is supported by the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). The randomized, Phase I trial in end-stage ischemic heart disease will include a ~10 patient open-label phase followed by a safety committee review, and then a ~24 patient randomized phase. Also validating for the company was BARDA’s recent notice of intent to exercise Option 1 of its contract with Cytori, which could be worth up to $35 million in non-dilutive funding to CYTX. Focus remains on the ATHENA Phase II program in chronic heart failure. ATHENA-I has 26 patients enrolled (target 45 by year end) and ATHENA-II has 3 patients enrolled. The study is enrolling 2-4 patients per month and the FDA has allowed expanding the number of clinical trial sites from 8 to 10 in ATHENAI and 10 to 12 in ATHENA-II. ATHENA-I data could read out in the mid-2015 time frame and management is encouraged by current enrollment trends”.

    Sentiment: Strong Buy

  • horse.ghost25 by horse.ghost25 Jul 23, 2014 10:40 AM Flag

    charts signals a change to the upside.

    Sentiment: Strong Buy

  • PBYI is an excellent example. Accumulate GALE at these lows.

    Sentiment: Strong Buy

  • Reply to

    Today's news is big people...

    by cytxer Jul 22, 2014 8:44 PM
    horse.ghost25 horse.ghost25 Jul 23, 2014 6:33 AM Flag

    Many who believe in the technolgy of CYTX have already bought, some long time ago still holding.
    so it is easy for the BOYZ to hold the pps down. only new buyers will help to rise the pps.
    they will come when the CYTX technolgy will be realized by more investors.

    Sentiment: Strong Buy

  • Reply to

    Motley Idiots provide poor analysis

    by rocketjock1 Jul 23, 2014 5:15 AM
    horse.ghost25 horse.ghost25 Jul 23, 2014 6:11 AM Flag

    no intelligent person would take these two giggling foolish idiots for serious. they obviously belong to the hedge pack trying to help to hold the pps down.

    Sentiment: Strong Buy

  • Reply to

    Where is Pearson hiding?

    by sygnett12 Jul 22, 2014 2:05 PM
    horse.ghost25 horse.ghost25 Jul 22, 2014 4:53 PM Flag

    yep, he should be put in prison imo together with his hedgefriends.

    Sentiment: Strong Buy

  • Feuerstein again spraying FUD and starting a new smear campaign. But less people listen to this pure nonsense talking hedgeclown.

    Sentiment: Strong Buy

  • Reply to

    LVAD trial handed to CYTX

    by jd39souza98 Jul 22, 2014 9:47 AM
    horse.ghost25 horse.ghost25 Jul 22, 2014 9:54 AM Flag

    Yep, agree, good time to add and accumulate. This news is another validation of the CYTX technology.

    Sentiment: Strong Buy

  • Reply to

    Zuplenz 1x10 for $229.99

    by biotechbuyer12 Jul 22, 2014 8:21 AM
    horse.ghost25 horse.ghost25 Jul 22, 2014 8:34 AM Flag

    very intelligent strategy of GALE to sell another good drug with the same salesforce! More revenue with the same salesforce. I expect they will try to aquire more drugs to sell with the same salesforce.

    Sentiment: Strong Buy

  • Reply to

    News Monday

    by peteshoka Jul 18, 2014 2:22 PM
    horse.ghost25 horse.ghost25 Jul 18, 2014 2:30 PM Flag

    volme too low

  • horse.ghost25 horse.ghost25 Jul 18, 2014 8:19 AM Flag

    The open-label, multi-center study is designed to investigate the preliminary efficacy and safety of aldoxorubicin in subjects with unresectable GBM whose tumors have progressed following prior treatment with surgery, radiation and temozolomide.

    The clinical trial is expected to enroll up to 28 subjects randomly assigned equally to two groups that will be administered either 350 mg/m2 (260 mg/m2 doxorubicin equivalent) or 250 mg/m2 (185 mg/m2 doxorubicin equivalent) of aldoxorubicin intravenously on Day 1, and every 21 days thereafter until evidence of tumor progression, unacceptable toxicity or withdrawal of consent. Tumor response will be monitored every 6 weeks by MRI until disease progression occurs. The trial is being conducted at the John Wayne Cancer Center/Sarcoma Oncology Center in Santa Monica, Calif., City of Hope in Duarte, Calif. and the Louisiana State University Health Sciences Center in New Orleans.

    Sentiment: Buy

  • horse.ghost25 horse.ghost25 Jul 18, 2014 3:18 AM Flag

    The scientists took advantage of the fact that tumors cover their increased energy needs, among other things, by taking up large amounts of the blood protein albumin. The researchers attached a fluorescent substance (5-aminofluorescein) to albumin, which is distributed throughout the body via the bloodstream and eventually accumulates in the brain tumor. Laser light causes the substance to glow and makes the fine extensions of the tumor visible.

    "Other contrast agents often fade," says Dr. Eva Frei, "for tumor resection can take five to six hours." The fluorescence marker attached to albumin, however, is visible during the entire operation.

    The scientists tested the albumin method in thirteen patients with malignant gliomas. In nine cases it was possible to remove the fluorescent tumor tissue completely thanks to the intensive yellow-green light signal. The researchers calculated that the probability of the glowing tissue being tumor cells is 97 percent.

    Sentiment: Strong Buy

  • Reply to

    If glioblastoma fails how far can this drop?

    by ownanalysis Jul 17, 2014 12:55 PM
    horse.ghost25 horse.ghost25 Jul 17, 2014 4:16 PM Flag

    thanks for that info.

    Sentiment: Buy

  • Reply to

    If glioblastoma fails how far can this drop?

    by ownanalysis Jul 17, 2014 12:55 PM
    horse.ghost25 horse.ghost25 Jul 17, 2014 2:59 PM Flag

    I guess it may fall to 3 or eventually to 2,8 or 2,60 and this would be a fantastic buying opportunity.
    or maybe it will go up from here, I don´t know for sure.
    Few words to GBM: I expect aldo will likely be succesfull, but we will see.
    Aldoxorubicin significantly increased survival almost 2½ fold compared to doxorubicin treatment in an xenograft tumor model employing growth of human glioblastoma multiforme (GBM) tumors in mouse brains.
    On the contrary doxorubicin doesnt had survival benefits.
    for example : overall median survival with doxorubicin let´s say would be 4 months (the same as placebo) . then aldoxorubicin would have 2½ fold increase of overall median survival, thats about.10 months and this is significant.
    - Aldoxorubicin also significantly reduced the number of dividing cells within the tumors and showed a statistically relevant increased expression of apoptosis biomarkers.
    - In comparison, doxorubicin did not appear to enter the tumor to any significant degree and showed no efficacy greater than saline in the treatment of these brain tumors
    These are the FACTS:
    aldo is 2½ fold increasing survival compared with doxo or placebo.
    aldo is entering the tumor with significant efficacy - doxo is not entering the tumor and has no efficacy.

  • Reply to

    Not looking good for CYTR

    by uvainvestor82 Jul 17, 2014 9:38 AM
    horse.ghost25 horse.ghost25 Jul 17, 2014 2:32 PM Flag

    the next support is now at 3,01

  • Reply to

    Not looking good for CYTR

    by uvainvestor82 Jul 17, 2014 9:38 AM
    horse.ghost25 horse.ghost25 Jul 17, 2014 2:28 PM Flag

    pps hit at first support 2,23

IMUC
0.89-0.03(-3.24%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.